Market Highlights

According to MRFR analysis, Human Immunodeficiency Virus (HIV) Drugs Market is expected to register a CAGR of 5% during the forecast period of 2019 to 2025 and was valued at USD 24 million in 2018.

HIV drugs aim to control the growth of the human immunodeficiency virus (HIV), improve the patient’s overall immune system, and reduce/stop the symptoms. The drugs used to treat HIV infection are antiretrovirals, which help reduce the viral load and fight the infection.

The growth of the global HIV drug market is driven by the increasing prevalence of HIV infection, rising awareness of HIV treatment, and the launch of innovative drugs. However, stringent regulatory policies for drug approval and product recalls are expected to curb the growth of the global HIV drug market during the assessment period. The global Human Immunodeficiency Virus (HIV) Drugs Market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Segmentation

The global HIV drug market has been segmented based on type and end-user. The market, based on type, has been divided into nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, integrase inhibitors, post-attachment inhibitors, and pharmacokinetic enhancers. The drugs in these different segments differ with respect to their mechanism of treating the HIV infection. The different approaches for treatment are, inhibiting HIV’s reverse transcriptase, preventing HIV maturation, and preventing the entry of the virus into the host cells, among others. The global Human Immunodeficiency Virus (HIV) Drugs Market has been segmented based on end-user, into hospitals & clinics, specialty centers, and others. The hospitals & clinics segment is expected to hold the largest market share due to an increasing number of hospitals.

Key Players

Some of the key players in the Global Human Immunodeficiency Virus (HIV) Drugs Market are Boehringer Ingelheim International, GmbH (Germany), Cipla Inc. (India), Merck & Co., Inc. (US), AbbVie Inc. (US), Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd (Israel), Gilead Sciences, Inc. (US), F.Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Aurobindo Pharma (India), Celltrion Healthcare Co., Ltd (South Korea), and ViiV Healthcare (UK).

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/hiv-drugs-market-8456

Regional Analysis  

The market has been divided, by region, into Europe, the Americas, Asia-Pacific, and the Middle East & Africa. The Americas holds the largest market share. The Human Immunodeficiency Virus (HIV) Drugs Market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. Europe is expected to be the second-largest market owing to factors such as product launches by key players. The European Human Immunodeficiency Virus (HIV) Drugs Market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Human Immunodeficiency Virus (HIV) Drugs Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the growing awareness regarding the use of HIV drugs and the increasing incidence of HIV in the region, the market in Asia-Pacific is expected to be the fastest-growing. The Human Immunodeficiency Virus (HIV) Drugs Market in the Middle East & Africa has been divided into the Middle East and Africa and is expected to hold the least market share.